Log In
Print
BCIQ
Print
Print this Print this
 

Relamorelin (RM-131) (formerly BIM 28131)

  Manage Alerts
Collapse Summary General Information
Company Ipsen Group
DescriptionGhrelin agonist
Molecular Target Ghrelin
Mechanism of ActionGhrelin agonist
Therapeutic ModalityPeptide

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$80.0M

0

$80.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today